OTLK - NASDAQ
Outlook Therapeutics, Inc.
$1.58
-0.94%Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
At a Glance
Live SnapshotOutlook Therapeutics, Inc. Management Team
Mr. Jeffrey Evanson
Chief Commercial Officer
Compensation
$451,170
Mr. Lawrence A. Kenyon CPA
EVice President, Chief Financial Officer, Interim Chief Executive Officer, Treasurer, Secretary & Director
Compensation
$476,170
Mr. Jedd Comiskey
Senior Vice President - Head of Europe
Dr. Jennifer M. Kissner Ph.D.
Senior Vice President of Clinical Development & Regulatory Affairs
Mr. Joel Prieve
Senior Vice President of Licensing and M&A
Dr. Surendra Sharma M.D.
Senior Vice President of Medical Affairs
Outlook Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.89M worth of OTLK shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
2.8M
2.89M
0
0.00
+2.9M
+$2.89M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Sukhtian Faisal Ghiath
Director
$423K
Haddadin Yezan Munther
Director
$400K
Hilzinger Kurt J
Director
$394K
Haller Julia A
Director
$360K
Auffarth Gerd
Director
$360K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $2.89M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
OTLK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | February 10, 2025 | March 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | June 26, 2024 | August 12, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | February 08, 2024 | March 07, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | February 15, 2023 | March 29, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | January 27, 2022 | March 23, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | February 22, 2021 | March 24, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | August 18, 2020 | September 17, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | February 14, 2020 | March 19, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | August 01, 2019 | September 12, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | August 17, 2018 | September 21, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.